Literature DB >> 28138626

HER2/neu as target in gastric adenocarcinoma.

Bulent Cetin1, Ahmet Ozet2.   

Abstract

Entities:  

Year:  2016        PMID： 28138626      PMCID： PMC5244761          DOI： 10.21037/tgh.2016.06.08

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  18 in total

1.  Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.

Authors:  Tao Wang; Eugene T Hsieh; Pauline Henry; Wedad Hanna; Catherine J Streutker; Andrea Grin
Journal:  Hum Pathol       Date:  2014-01-08       Impact factor: 3.466

2.  Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.

Authors:  Carlos Gomez-Martin; Jose Carlos Plaza; Roberto Pazo-Cid; Antonieta Salud; Francesc Pons; Paula Fonseca; Ana Leon; Maria Alsina; Laura Visa; Fernando Rivera; M Carmen Galan; Elena Del Valle; Felipe Vilardell; Mar Iglesias; Soledad Fernandez; Stefania Landolfi; Miriam Cuatrecasas; Marta Mayorga; M Jose Paulés; Pilar Sanz-Moncasi; Clara Montagut; Elena Garralda; Federico Rojo; Manuel Hidalgo; Fernando Lopez-Rios
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

3.  The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples.

Authors:  Federica Grillo; Matteo Fassan; Chiara Ceccaroli; Cinzia Giacometti; Monica Curto; Vittorina Zagonel; Paola Ceppa; Donato Nitti; Carlo Castoro; Roberto Fiocca; Massimo Rugge; Luca Mastracci
Journal:  Transl Oncol       Date:  2013-02-01       Impact factor: 4.243

4.  Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma.

Authors:  P van Hagen; K Biermann; J E Boers; O Stoss; H F Sleddens; J J B van Lanschot; W N M Dinjens; J Rueschoff; B P L Wijnhoven
Journal:  Dis Esophagus       Date:  2014-03-10       Impact factor: 3.429

5.  HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio?

Authors:  Marian Priyanthi Kumarasinghe; Willem Bastiaan de Boer; Tze Sheng Khor; Esther M Ooi; Nic Jene; Sureshini Jayasinghe; Stephen B Fox
Journal:  Pathology       Date:  2014-04       Impact factor: 5.306

6.  Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.

Authors:  Jihun Kim; Cameron Fox; Shouyong Peng; Mark Pusung; Eirini Pectasides; Eric Matthee; Yong Sang Hong; In-Gu Do; Jiryeon Jang; Aaron R Thorner; Paul Van Hummelen; Anil K Rustgi; Kwok-Kin Wong; Zhongren Zhou; Ping Tang; Kyoung-Mee Kim; Jeeyun Lee; Adam J Bass
Journal:  J Clin Invest       Date:  2014-11-17       Impact factor: 14.808

7.  Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

Authors:  J Randolph Hecht; Yung-Jue Bang; Shukui K Qin; Hyun C Chung; Jianming M Xu; Joon O Park; Krzysztof Jeziorski; Yaroslav Shparyk; Paulo M Hoff; Alberto Sobrero; Pamela Salman; Jin Li; Svetlana A Protsenko; Zev A Wainberg; Marc Buyse; Karen Afenjar; Vincent Houé; Agathe Garcia; Tomomi Kaneko; Yingjie Huang; Saba Khan-Wasti; Sergio Santillana; Michael F Press; Dennis Slamon
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

8.  HER2 expression variability between primary gastric cancers and corresponding lymph node metastases.

Authors:  Zhejun Qiu; Weidong Sun; Chengzhong Zhou; Jiandong Zhang
Journal:  Hepatogastroenterology       Date:  2015 Jan-Feb

9.  Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.

Authors:  C Bozzetti; F V Negri; C A Lagrasta; P Crafa; C Bassano; I Tamagnini; G Gardini; R Nizzoli; F Leonardi; D Gasparro; R Camisa; S Cavalli; S Capelli; E M Silini; A Ardizzoni
Journal:  Br J Cancer       Date:  2011-04-12       Impact factor: 7.640

10.  Comprehensive molecular characterization of gastric adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962
View more
  3 in total

1.  Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.

Authors:  Caiyun Nie; Yunduan He; Huifang Lv; Ming Gao; Xiaohui Gao; Beibei Chen; Weifeng Xu; Jianzheng Wang; Yingjun Liu; Jing Zhao; Xiaobing Chen
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

2.  Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer.

Authors:  Juan-Cheng Yang; Ning Chang; Deng-Chyang Wu; Wei-Chung Cheng; Wei-Min Chung; Wei-Chun Chang; Fu-Ju Lei; Chung-Jung Liu; I-Chen Wu; Hsueh-Chou Lai; Wen-Lung Ma
Journal:  J Cell Mol Med       Date:  2019-09-26       Impact factor: 5.310

3.  Ursolic acid silences CYP19A1/aromatase to suppress gastric cancer growth.

Authors:  Wen-Lung Ma; Ning Chang; Yingchun Yu; Yu-Ting Su; Guan-Yu Chen; Wei-Chung Cheng; Yang-Chang Wu; Ching-Chia Li; Wei-Chun Chang; Juan-Cheng Yang
Journal:  Cancer Med       Date:  2022-05-11       Impact factor: 4.711
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.